ES
CAMP icon

Enavate Sciences’s CAMP4 Therapeutics CAMP Stock Holding History

Enavate Sciences’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.23M Sell
1,425,541
-765,379
-35% -$3.3M 1.8% 7
2026
Q1 		$9.66M Sell
2,190,920
-844,905
-28% -$4.01M 2.75% 7
2025
Q4 		$18.6M Sell
3,035,825
-749,977
-20% -$3.19M 3.67% 7
2025
Q3 		$11.4M Hold
3,785,802
– – 3.47% 7
2025
Q2 		$5.49M Hold
3,785,802
– – 3.11% 6
2025
Q1 		$15.1M Hold
3,785,802
– – 11.41% 4
2024
Q4 		$19.8M Buy
+3,785,802
New +$31.1M 14.19% 4

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Enavate Sciences's CAMP Position: Q2 2026 in Review

Enavate Sciences reduced its CAMP4 Therapeutics (CAMP) stake by 35% in Q2 2026, selling an estimated $3.3M and leaving 1,425,541 shares worth $6.23M. The position accounts for 1.8% of the portfolio, ranked #7.

Enavate Sciences first reported a position in CAMP in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.8M in Q4 2024. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Enavate Sciences held 1,425,541 shares of CAMP4 Therapeutics worth $6.23M as of Q2 2026.
  • Enavate Sciences sold 765,379 CAMP4 Therapeutics shares in Q2 2026, an estimated $3.3M.
  • CAMP4 Therapeutics made up 1.8% of Enavate Sciences's portfolio in Q2 2026, its #7 holding.
  • Enavate Sciences first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Enavate Sciences's CAMP4 Therapeutics position peaked at $19.8M in Q4 2024.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Enavate Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.